Study S000724

CSP #2041 - Cessation or Reduction of Alcohol Consumption in VEterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder (CRAVE)

ClinicalTrials.gov record

Registration

Registration: NCT07218354
Acronym: CRAVE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 622
Start: 2026-07-28
Primary completion: 2029-03-31
Lead sponsor: VA Office of Research and Development
Conditions: Alcohol Use Disorder
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Two-level reduction in the World Health Organization (WHO) risk drinking level assessed in the last 28 days of intervention [Change from baseline (after randomization) to change in the last 28 days of the intervention]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.